To the Editor—An antimicrobial stewardship program (ASP) can be defined as the set of actions performed in hospitals for the rational use of antibiotics; reduction of adverse events, dosage errors, and appearance of multidrug-resistant bacteria; and shortening of length of hospital stay. The performance of the professional team implementing these programs, including clinical pharmacists, physicians and nurses, is associated with reduced in-hospital mortality rates.^{Reference Okumura, Silva and Veroneze1} Managed antimicrobial administration programs shorten the length of hospital stay and reduce costs associated with the use of these medications.

Antibiotics account for a considerable cost in hospital bills, accounting for almost 20% of drug costs in Brazilian intensive care units.^{Reference Gasparetto, Tuon and Dos Santos Oliveira2} The usage policy is a controversial subject because it varies among hospitals. De-escalation of therapy and a switch from an intravenous to oral regimen, if it does not cause harm and demonstrates a safe strategy, can have an important outcome.^{Reference Schuts, Hulscher and Mouton3}

ASPs are safe and cost-effective, an approach important particularly in developing countries.^{Reference Boyles, Whitelaw and Bamford4} We demonstrated an estimated savings of US$514,831 as a result of the implementation of the stewardship program in 2 institutions. These numbers encourage hospital administrators because there is always pressure to reduce costs. However, since the implementation of the ASPs in our hospitals, the price of medications has increased disproportionately. Figure 1 clearly shows the disproportionate increasing in the price of antimicrobials purchased by our group of hospitals in relation to various value indices.

Fig. 1.

Prices of 2 essential antibiotics, cefazolin (CFZ) and ceftriaxone (CRO), in the last 4 years, showing increasing costs, instead of aminoglycosides, amikacin (AMK), and gentamicin (GEN). The dark-gray columns indicate the price of each antibiotic and the light-gray columns indicate the maximum price allowed in Brazil. The dashed lines are the market index, IPCA for consumer prices, and CMED for drugs. Note. PP, purchase price; MP, maximum price; IPCA, Brazilian Broad Consumer Price Index; CMED, Brazilian Drugs Market Regulation Chamber.

The cost of some antibiotics increased >500% over a period of 1 year (Fig. 1). This situation has led to a series of measures within our hospitals to contain costs to maintain the viability of our public hospital. We changed the surgical prophylaxis protocol from cefazolin to clindamycin. We implemented an active ASP for switching from an intravenous to an oral regimen as well as a de-hospitalization program (ie, outpatient antimicrobial therapy with oral and intravenous options). This cost crisis could be a stimulus to improve the ASP, but it will be discouraging if a cost reduction is not achieved.

In Brazil, the pricing of medicine is regulated by an agency called CMED (cf, Drug Market Regulation Chamber), which defines the maximum drugs prices that can be sold and the readjustment rates (Law no. 10.742, October 6, 2003). Annual escalation is calculated using an equation which IPCA (Broad Consumer Price Index), the official Brazilian inflation index, is the main variable (Decree no. 4,937, December 29, 2003). The accumulated CMED escalation amounted to 11.93% in the studied period, while the purchase prices of cefazolin and ceftriaxone (the antibiotics of choice for surgical prophylaxis and for treatment of pneumonia, urinary tract infections, meningitis, and intra-abdominal infections) increased 617% and 292%, respectively. On the other hand, amikacin and gentamicin, old drugs that are discouraged due to adverse reactions, suffered a 0.9% reduction and a 3% increase in the purchase price. Despite the disproportionate increase, the purchase prices did not exceed the maximum prices allowed by CMED. However, the annual trend suggests that the prices charged by laboratories and distributors will be very close to the maximum price allowed for widely marketed hospital antibiotics.

Recently, a small Missouri-based drug maker more than quadrupled the price of nitrofurantoin.^{Reference Crow5} In an interview, the chief executive said he had priced the product according to market dynamics and that it is a moral requirement to make money when you can. Furthermore, he said that this is a capitalist economy, and if you cannot make money, you cannot stay in business.

Clearly, antibiotic prices in Brazil are uncontrolled and antibiotics are in demand from suppliers. Antibiotics are considered the most important drugs in the treatment of serious infections. Many hospitals have avoided the most expensive antibiotics, but this may compromise the treatment of patients. Cost should be part of the ASP, but it should not be the main engine of an amazing model of therapeutic rationalization.